A nutritional composition for elderly patients after digestive tract tumor resection
Through the protein composition of casein, whey protein and soy protein in a specific proportion, the gastrointestinal tolerance and muscle protein synthesis requirements of elderly patients after gastrointestinal tumor resection are solved, and rapid wound healing and continuous weight inhibition are achieved. Lost effects.
Patent Information
- Application Number
- CN202210172331.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-02-24
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2042-02-24
AI Technical Summary
Existing enteral nutritional preparations are difficult to meet the needs of gastrointestinal tolerance, rapid wound healing and continuous muscle protein synthesis in elderly patients after gastrointestinal tumor resection, resulting in postoperative wound healing and weight loss.
Protein compositions combined with casein, whey protein and soy protein in specific proportions (such as 48:28:24) meet the needs of wound healing and muscle protein synthesis by optimizing gastrointestinal tolerance and plasma amino acid release rates.
It significantly improved the gastrointestinal tolerance of elderly patients after gastrointestinal tumor resection, quickly promoted wound healing, and continued to inhibit weight loss, meeting postoperative nutritional needs.
Smart Images

Figure CN116687003B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a nutritional composition, in particular to a protein composition with good gastrointestinal tolerance, which accelerates the regeneration of wound tissue and continuously enhances muscle protein synthesis, thereby promoting wound healing and inhibiting weight loss in elderly patients after gastrointestinal tumor resection. Background Art
[0002] Gastrointestinal tumors are common malignant tumors in the elderly. The incidence of gastrointestinal tumors in the elderly increases with age. Surgical resection is a common means of treating gastrointestinal tumors, that is, resection of all or part of the organs at the site of disease. The relatively high proportion of surgical sites are the stomach, esophagus, colon, rectum, etc., which have high clinical application value. However, due to the particularity of the anatomical structure of the digestive tract, patients may experience varying degrees of gastrointestinal damage and digestion and absorption dysfunction. Common postoperative manifestations of malnutrition such as slow wound healing and progressive weight loss directly affect clinical prognosis. Taking appropriate nutritional therapy to shorten the wound healing time after resection and continuously inhibit weight loss has undoubtedly become the focus of attention of clinicians and nutritionists. In view of this, we must also note that, on the one hand, elderly patients are weak in constitution and are affected by disease factors such as digestive tract tumors in different parts. Digestive and absorption dysfunction is more obvious in elderly patients. In addition, the tolerance of postoperative patients to enteral nutrition is different, which increases the risk of gastrointestinal intolerance such as abdominal distension, diarrhea, abdominal pain, and gastroparesis, further highlighting the contradiction of insufficient food intake while energy-protein is in a high metabolic state. Therefore, clinical screening NRS 2002 total score ≥ 3 points in malnutrition patients is more common, and the loss rate of lean muscle and lean body weight is faster; on the other hand, surgical trauma accelerates protein decomposition, aggravates protein malnutrition, and is more prone to complications such as infection and anastomotic fistula, especially the severe delay in postoperative tissue trauma recovery, resulting in a high risk of long-term bed rest and bedsores, which seriously affects the treatment and prognosis. The above problems are mutually causal, forming a vicious cycle, which makes it difficult to fully solve the disease problem and the condition is prolonged and repeated. For this reason, it is particularly important to accelerate recovery, shorten the healing time, and reduce the pain of patients in the early stage of enteral nutrition after gastrointestinal tumor resection in the elderly.
[0003] Adequate nutritional supply is essential. We believe that the enteral nutrition therapy for elderly patients after gastrointestinal tumor resection should meet three attributes at the same time. The first is good gastrointestinal tolerance, which is of great significance to ensure patient compliance with the continuous implementation of nutritional therapy; the second is to accelerate wound tissue repair, meet the urgency of wound healing in postoperative patients, and reduce the incidence of complications such as infection and anastomotic leakage; the third is to counteract the high metabolic effect of muscle breakdown, meet the rigid needs of tumor patients to enhance the continuous synthesis of muscle protein and maintain weight loss, and avoid the occurrence and development of tumor cachexia. Unfortunately, there are currently few protein compositions that meet the above three attributes at the same time.
[0004] Enteral nutrition preparations currently being commercialized or studied are beneficial to cancer or surgical patients to a certain extent, but it is difficult to fully adapt to the clinical prognosis of elderly patients after gastrointestinal tumor resection. There are three main sources of product protein, which are analyzed as follows:
[0005] One is the whole protein type. ① The main source of protein is casein: Casein is often classified as a gastric coagulation protein and has the risk of gastrointestinal intolerance. For example, Rueneng (Fresenius Kabi Huarui Pharmaceutical Co., Ltd.), which is used for enteral nutrition of cancer patients, has casein as the only source of protein. Therefore, it is not difficult to understand that the drug instructions clearly define contraindications as "decreased gastrointestinal tone, acute pancreatitis, and diseases with severe digestive and absorptive disorders. This product is contraindicated for use in patients with cachectic tumors who have no contraindications. However, the product has obvious advantages in enhancing the continuous synthesis of body protein (especially muscle tissue growth) and can significantly inhibit weight loss in tumor patients. There are also complete nutritional formula foods on the market that use milk protein (casein accounts for 80%) as a nitrogen source that are beneficial to cancer patients. For example, PROSURE sold by Abbott Laboratories and RESOURCE SUPPORT sold by Novartis, the protein is provided by isolated milk protein (casein: whey protein = 8:2), which can help muscles grow continuously and help maintain body weight. It is used for patients undergoing radiotherapy and chemotherapy to fight muscle catabolism, cachexia or anorexia, ensuring good support for patients' energy and vitality. ② Protein source is whey protein: Whey protein is often classified as a non-gastric coagulating protein with good gastrointestinal tolerance. For example, IMPACT sold by Nestle, the protein is provided by whey protein and is used for nutritional treatment of surgical patients. The above examples are an affirmation of the advantages of products using casein as the main nitrogen source in continuously maintaining muscle growth, and are also an affirmation of the advantages of products using whey protein as the main nitrogen source in postoperative wound repair; however, the inventors observed in the experiment in Example 3 that casein forms protein coagulation at gastric pH, and therefore shows reduced digestibility, which undoubtedly limits its use in rapidly increasing plasma essential amino acid levels and promoting wound healing; while whey protein does not form protein coagulation at gastric pH, has a high gastric emptying rate, and shows high digestibility, and thus the in vivo metabolic rate of plasma essential amino acid levels is also faster, and plasma essential amino acids cannot be maintained at a high level for a long time, which undoubtedly limits its use in continuously enhancing the growth of muscle tissue, and requires a longer period of intervention to be effective.
[0006] The second is the hydrolyzed protein type. For example, the short peptide enteral nutrition suspension Bipro (Nutricia Pharmaceuticals Co., Ltd.), the protein source is hydrolyzed whey protein, which is suitable for patients with gastrointestinal function or partial gastrointestinal function who cannot or are unwilling to eat a sufficient amount of conventional food to meet the body's nutritional needs. It is mainly used for metabolic gastrointestinal dysfunction (including pancreatitis, intestinal inflammatory diseases, radiation enteritis and chemotherapy, intestinal fistula, short bowel syndrome, etc.), and is also suitable for the recovery period of critical diseases such as trauma and major surgery; there are no contraindications for patients with related digestive and absorption disorders, and the only adverse reaction in the drug instructions is that "the use of this product may cause diarrhea, abdominal pain and other gastrointestinal discomfort reactions", indicating that hydrolyzed whey protein has largely solved the gastrointestinal tolerance problem compared to the whole protein nitrogen source. At this point, it is necessary to further evaluate and compare the efficacy of hydrolyzed whey protein and intact whey protein on postoperative tissue repair. It is generally believed that hydrolyzed whey protein has a smaller molecular weight than intact whey protein, a faster digestion and absorption rate in the body, and should be better than whey protein in repairing traumatic tissues. However, in fact, the ability of whey protein to postoperative tissue repair may be better than hydrolyzed whey protein, as the inventor unexpectedly found, the ability of isolated whey protein to promote wound healing of zebrafish after tail amputation is obviously better than hydrolyzed whey protein (see Example 5), which completely overturns traditional cognition. Possible mechanism is that complete whey protein contains alpha-lactalbumin (15g / 100g), beta-lactoglobulin, serum albumin and immunoglobulin, which is the main nutrient for the formation and growth of tissue, and hydrolyzed whey protein may have some functional groups cut off by enzymolysis in the enzymolysis preparation process, and the protein active structural unit that promotes wound healing may be destroyed, and the ability of forming and repairing tissue is not as good as complete whey protein. It can be seen that the relatively good hydrolyzed whey protein of gastrointestinal tolerance is not as good as whey protein to the effectiveness of wound healing, and the same conditions should preferably be the treatment scheme of the equally acceptable complete whey protein of gastrointestinal tolerance as the main nitrogen source. The above examples are a relative affirmation of the clinical advantages of products with hydrolyzed whey protein as the main nitrogen source for gastrointestinal tolerance and promoting wound healing; however, similar to whey protein, the inventors note that the gastric emptying rate of hydrolyzed whey protein is high, and the in vivo metabolic rate of plasma essential amino acid levels due to high digestibility is also fast, and plasma essential amino acids cannot be maintained at a high level for a long time. The use for continuous maintenance of muscle tissue growth is undoubtedly also limited. This was confirmed in a clinical study by the Department of Nutrition of the First Medical Center of the General Hospital of the People's Liberation Army (Zhang Xinsheng, et al. A multicenter randomized controlled study on the effects of supplementation with hydrolyzed whey protein on hypoproteinemia and body composition in patients after gastrectomy. Chinese Food and Nutrition. 2021, 27 (11): 57-64).The results showed that oral supplementation of hydrolyzed whey protein and isolated whey protein had good gastrointestinal tolerance in patients after gastrectomy. A decrease in the incidence of postoperative gastrointestinal diarrhea and constipation and an improvement in serum low protein levels were observed after 7 days of intervention. However, the increase in lean body mass and lean body mass percentage required 21 days of intervention to be significantly different from the control group, indicating that the effectiveness of hydrolyzed whey protein and isolated whey protein in enhancing the continuous synthesis of muscle tissue protein is relatively low, and a longer intervention period is required to be effective.
[0007] Third, a combination of gastric coagulating protein and non-gastric coagulating protein. Many researchers have tried to provide a protein composition with casein as the main component, which will not coagulate in the upper gastrointestinal tract, has good gastrointestinal tolerance, and can be used to promote wound healing. A possible idea is to combine casein with non-gastric coagulating protein with good gastrointestinal tolerance in a certain proportion. FrieslandCampina Netherlands has disclosed two patents, among which patent CN 111246872 A (protein-dense nutritional composition for treating and / or preventing muscle mass and / or strength loss-related diseases) describes the use of a liquid high-protein composition composed of micellar casein and hydrolyzed whey protein in a weight ratio ranging from 40:60 to 90:10; patent CN111836555A (highly digestible protein-rich nutritional composition, its use and preparation method) describes a composition of non-coagulating protein (whey protein) and coagulating protein (casein or caseinate) in a relative weight ratio ranging from 22:78 to 70:30. Both of the above patents propose that a composition of casein with a relatively large proportion of hydrolyzed whey protein or whey protein can be used to increase plasma leucine levels, enhance muscle protein synthesis, and treat and / or prevent diseases related to loss of muscle mass and / or strength, but the above patents do not involve the therapeutic use of the composition to accelerate wound healing. Theoretically, a composition with a relatively small proportion of non-gastric coagulated whey protein or hydrolyzed whey protein and a relatively large proportion of gastric coagulated casein still has the risk of forming protein coagulation at gastric pH, and thus still has reduced digestibility, which undoubtedly limits its use in rapidly increasing plasma essential amino acid levels and promoting wound healing. In addition, Nestle's ZL 200480037170.1 (Nutritional composition for wound healing) describes a nutritional composition of 50% sodium caseinate, 45% concentrated milk protein, 3% proline, and 2% arginine by weight; CN102083329B (High-protein liquid enteral nutritional composition) describes a nutritional composition of at least 85-95% whey protein by weight, 10-40% casein or caseinate by weight, and 0.5-5% free amino acids by weight. Both of the above patents prove that a composition of whey protein and casein with a large proportion can be used for elderly patients who need postoperative wound healing, malnourished patients who are in a disease state or recovering from a disease state, but the above patents do not involve the description of the use of the composition for muscle protein synthesis. Theoretically speaking, a composition with a smaller proportion of gastric coagulated casein and a larger proportion of non-gastric coagulated whey protein has high digestibility, which results in the inability to maintain high plasma essential amino acids for a long time. This undoubtedly limits its use for continuously enhancing the growth of muscle protein synthesis, and requires a longer intervention period to be effective.
[0008] According to the above analysis, the protein provided by existing commercial enteral nutrition preparations cannot simultaneously meet the three property requirements of good gastrointestinal tolerance, rapid promotion of wound tissue repair, and continuous enhancement of muscle tissue growth. It is difficult to meet the clinical nutritional needs of elderly patients after gastrointestinal tumor resection, who need to both rapidly promote wound healing and continuously inhibit weight loss. In view of this, choosing a suitable nitrogen source with the above three properties is the key to solving the problem. Summary of the invention
[0009] Due to the inherent gastrointestinal intolerance of proteins provided by commercial products and the varying degrees of nutritional adequacy defects, the actual protein intake of elderly patients after gastrointestinal tumor resection is seriously insufficient and cannot meet the nutritional needs of the above special populations for protein. Referring to relevant domestic and foreign guidelines (Chinese Society of Parenteral and Enteral Nutrition. Guidelines for Perioperative Nutrition Support in Adults. Chinese Journal of Surgery. 2016, 54(9): 641-657, McClave SA, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN). JPEN 2016, 40(2): 159-211), the target protein requirement for elderly patients after gastrointestinal tumor resection is 1.5-2.0 g / (kg·d). In view of this, improving the gastrointestinal tolerance of protein to ensure compliance with continuous nutritional therapy, optimizing the nutritional adequacy of protein to quickly promote wound healing, and continuously inhibiting weight loss are the primary goals that need to be urgently addressed in providing the above patient populations with sufficient quantity and quality protein.
[0010] More and more clinical nutrition consensus (Han Junhua. Implementation Guidelines for a Series of Standards for Composition Foods for Special Medical Purposes, China Quality Inspection / Standards Press, 2015: 149) points out that the quality of protein plays an important role in the synthesis of body proteins. Due to the different digestibility and bioavailability of different proteins, the concept of dividing proteins into "fast protein" and "slow protein" has been proposed, and in recent years, "medium protein" has also been defined. The characteristic of "fast protein" is that it can appear in the blood in the form of amino acids quickly after digestion, the characteristic of "slow protein" is that the rate of increase of amino acids in plasma after a meal is slow, and the characteristics of medium protein are between fast and slow proteins. Whey protein is a typical fast protein; casein is a typical slow protein because it forms clots in the stomach, which causes it to be released into the blood at a slow rate; soy protein has a digestibility and bioavailability between whey protein and casein, and is a typical medium protein. Since the patient compliance of enteral nutrition, the rapid repair ability of wound tissue and the continuous synthesis ability of muscle protein depend on the gastric coagulation property of protein, the degree and time of the increase of amino acids in plasma (including the onset time and the maintenance time), the formulation design goal is to meet the three property requirements of good gastrointestinal tolerance, rapid promotion of wound tissue repair and continuous enhancement of muscle tissue growth, with reference to Nestlé ZL 200480037170.1 (nutritional composition for wound healing) and Nestlé approved special medical purpose formula food Jiashenxuan (National Food Note TY20195007), based on the basic formula of "casein: whey protein = 50:50 (weight ratio), the present invention adopts the idea of replacing part of the fast protein or slow protein with an intermediate protein, and designs the following three schemes, trying to screen out a special compatibility ratio, and cleverly combines casein, whey protein, and soy protein, three proteins with different digestibility and different release rates, in order to solve the confusion of nutritional treatment for elderly patients after gastrointestinal tumor resection.
[0011] The first option sets the weight ratio of fast protein to approximately 50%, and uses intermediate protein to replace part of the slow protein ratio. Based on the existing knowledge and reasoning about the digestibility and bioavailability of the three proteins, in principle, this combination protein can optimize gastrointestinal tolerance and retain the advantage of accelerated wound healing. However, it is still uncertain whether it has the ability to continuously enhance muscle protein synthesis?
[0012] The second option sets the weight ratio of slow protein at approximately 50%, and uses intermediate protein to replace part of the proportion of fast protein. Based on the existing cognitive reasoning about the digestibility and bioavailability of the three proteins, this combination protein can retain its ability to continuously enhance muscle protein synthesis and control weight loss. In principle, it should be better than option one. However, it is still uncertain whether it has good gastrointestinal tolerance and whether it has the ability to accelerate wound tissue regeneration and promote wound healing.
[0013] The third option sets the weight ratio of intermediate protein at approximately 50%, and uses intermediate protein to replace part of the proportion of fast protein and slow protein. Based on the existing cognitive reasoning about the digestibility and bioavailability of the three proteins, the gastrointestinal tolerance and ability to promote wound healing of this combination protein may be better than those of option two, and the ability to continuously enhance muscle protein synthesis may be between options one and two. This requires comparative research to verify the specific details.
[0014] The performance of the above three schemes is only a prediction, and its accuracy cannot be determined yet. Based on existing cognition and reasoning, we believe that the scheme that meets all the technical attribute requirements of the present invention may be in Scheme 2 or Scheme 3. Theoretically, in terms of gastrointestinal tolerance, Scheme 2 and Scheme 3 should be far inferior to Scheme 1, which is mainly fast protein, but Scheme 3, which is mainly intermediate protein, may be better than Scheme 2, which is mainly slow protein; in terms of the ability to accelerate wound healing, Scheme 3 may also be better than Scheme 2. To this end, we need to compare ① Taking whey protein as the reference protein, examine the difference in gastrointestinal tolerance between Scheme 2, Scheme 3 and Scheme 1? Is Scheme 3 better than Scheme 2? ② Taking casein as the reference protein, examine the difference in the ability of Scheme 3, Scheme 1 and Scheme 2 to continuously enhance muscle protein synthesis. Is Scheme 3 better than Scheme 1? ③ Using the model of increased protein demand after surgery as a control, examine the difference in the ability of Scheme 2, Scheme 3 and Scheme 1 to accelerate tissue regeneration. Is Scheme 3 better than Scheme 2?
[0015] The present invention surprisingly found that the second scheme retains the advantage of a larger proportion of casein, replaces part of the whey protein with soy protein, and designs a nutritional composition composed of casein, whey protein and soy protein in a specific ratio. This ratio makes it possible to maximize the advantages of the three different protein sources, achieving the three property requirements of good gastrointestinal tolerance, accelerated wound tissue repair, and continuous enhancement of muscle tissue growth, and can meet the clinical nutritional needs of elderly patients after gastrointestinal tumor resection to promote wound healing quickly and continuously suppress weight loss. It can be said that the nitrogen source provided by the composition designed according to scheme 2 of the present invention is a nutritional composition of a special ratio, which was unexpectedly found and confirmed to show a more excellent effect than the composition designed under the ideas of schemes 1 and 3, thereby completing the present invention.
[0016] The purpose of the present invention is to provide a digestible high-quality protein with good gastrointestinal tolerance. On the one hand, it accelerates the wound healing of elderly patients after gastrointestinal tumor resection by accelerating the regeneration of traumatic tissue; on the other hand, it continuously enhances the synthesis of muscle protein, significantly inhibits the progressive weight loss caused by malnutrition due to tumors and postoperative hypoproteinemia, and comprehensively improves the clinical outcome.
[0017] The nutritional composition provided by the present invention consists of 48 parts by weight of casein, 28 parts by weight of whey protein, and 24 parts by weight of soy protein, wherein the casein is selected from casein free form (such as micellar casein) or caseinate form (such as potassium caseinate, sodium caseinate, calcium caseinate, magnesium caseinate) and any mixture thereof; the whey protein is selected from concentrated whey protein, isolated whey protein and any mixture thereof; the soy protein is selected from isolated soy protein.
[0018] The protein content (on a wet basis) of the nutritional composition provided by the present invention is not less than 83.0%, wherein the protein content (on a wet basis) of the casein shall not be less than 83.5%; the protein content (on a wet basis) of the whey protein shall not be less than 75.0%; and the protein content (on a wet basis) of the soy protein isolate shall not be less than 85.0%.
[0019] In one embodiment of the present invention, the nutritional composition is composed of 48 parts by weight of micellar casein, 28 parts by weight of isolated whey protein, and 24 parts by weight of isolated soy protein, and the protein content of the composition (on a wet basis) is 87.7%; the protein content of micellar casein (on a wet basis) is 84.5%, the protein content of isolated whey protein (on a wet basis) is 93.0%; and the protein content of isolated soy protein (on a wet basis) is 88.0%.
[0020] In one embodiment of the present invention, the nutritional composition is composed of 48 parts by weight of calcium caseinate, 28 parts by weight of concentrated whey protein, and 24 parts by weight of soy protein isolate, and the protein content of the composition (on a wet basis) is 86.9%; the protein content of calcium caseinate (on a wet basis) is 92.2%, the protein content of concentrated whey protein (on a wet basis) is 77.0%; and the protein content of soy protein isolate (on a wet basis) is 88.0%.
[0021] In one embodiment of the present invention, the nutritional composition is composed of 24 parts by weight of micellar casein, 24 parts by weight of calcium caseinate, 14 parts by weight of isolated whey protein, 14 parts by weight of concentrated whey protein, and 24 parts by weight of soy protein isolate, and the protein content of the composition (on a wet basis) is 87.4%; the protein content of micellar casein and calcium caseinate (on a wet basis) is 84.5% and 92.2%, respectively, the protein content of isolated whey protein and concentrated whey protein (on a wet basis) is 93.0% and 77.0%, respectively; the protein content of soy protein isolate (on a wet basis) is 88.0%.
[0022] In one embodiment of the present invention, the nutritional composition is composed of 40 parts by weight of calcium caseinate, 8 parts by weight of sodium caseinate, 20 parts by weight of concentrated whey protein, 8 parts by weight of isolated whey protein, and 24 parts by weight of soy protein isolate, and the protein content of the composition (on a wet basis) is 88.2%; the protein content of calcium caseinate and sodium caseinate (on a wet basis) is 92.2% and 90.6%, respectively, the protein content of isolated whey protein and concentrated whey protein (on a wet basis) is 93.0% and 77.0%, respectively; the protein content of soy protein isolate (on a wet basis) is 88.0%.
[0023] In one embodiment of the present invention, the nutritional composition is composed of 20 parts by weight of micellar casein, 20 parts by weight of calcium caseinate, 8 parts by weight of potassium caseinate, 28 parts by weight of isolated whey protein, and 24 parts by weight of isolated soy protein, and the protein content of the composition (on a wet basis) is 89.9%; the protein contents of micellar casein, calcium caseinate and potassium caseinate (on a wet basis) are 84.5%, 92.2% and 91.8%, respectively, the protein content of isolated whey protein (on a wet basis) is 93.0%; the protein content of isolated soy protein (on a wet basis) is 88.0%.
[0024] In one embodiment of the present invention, the nutritional composition is composed of 12 parts by weight of micellar casein, 12 parts by weight of calcium caseinate, 24 parts by weight of magnesium caseinate, 28 parts by weight of concentrated whey protein, and 24 parts by weight of soy protein isolate, and the protein content of the composition (on a wet basis) is 85.5%; the protein contents of micellar casein, calcium caseinate and magnesium caseinate (on a wet basis) are 84.5%, 92.2% and 90.3%, respectively, the protein content of concentrated whey protein (on a wet basis) is 77.0%; the protein content of soy protein isolate (on a wet basis) is 88.0%.
[0025] The casein, whey protein and soy protein used in the composition of the present invention can all be obtained from commercial sources, such as casein or caseinate can be commercially available from companies such as Friesland Campina and Fonterra (Nzmp); concentrated whey protein or isolated whey protein can be commercially available from companies including Arla Foods Ingredients SA, Glanbia Nutritionals, Hilmar, Agropur and Tatua; soy protein isolate can be commercially available from companies such as DuPont (Dupout) and its domestic manufacturers.
[0026] Another object of the present invention is to provide a product form of the composition in the form of an oral preparation, which can be any one of a powder, a granule, and a suspension emulsion. The preparation method of the oral preparation of the composition is as follows:
[0027] In one embodiment of the present invention, the preparation method of the oral powder of the composition is as follows: after the three raw materials of casein, whey protein and soy protein that meet the quality requirements of protein content are accepted and tested, the materials are prepared, weighed and sieved according to the formula and dosage shown in Example 1, and added to a two-dimensional motion mixer in sequence, and an appropriate amount of silicon dioxide or other anti-caking agent is added, mixed for 10 to 30 minutes, the rotation speed is 10 to 20 rpm, and quantitative packaging is performed.
[0028] In one embodiment of the present invention, the preparation method of the oral granules of the composition is as follows: after the three raw materials of casein, whey protein and soy protein that meet the quality requirements of protein content are accepted and inspected, the materials are prepared, weighed and sieved according to the formula and dosage shown in Example 1, and added to the fluidized bed granulator in sequence, mixed, sprayed with an appropriate amount of water as a binder for wet granulation, dried, sieved, granulated, and quantitatively packaged.
[0029] In one embodiment of the present invention, the preparation method of the oral suspension emulsion of the composition is as follows: after the three raw materials of casein, whey protein and soy protein that meet the quality requirements of protein content are accepted and inspected, the materials are prepared, weighed and sieved according to the formula and dosage shown in Example 1, and added to the liquid preparation tank containing an appropriate amount of purified water in sequence, stirred and mixed, an appropriate amount of emulsifying thickener is added, and after shearing, homogenization, volume setting, filling and other processes, sterilization is performed at 121°C for 15 minutes.
[0030] In one embodiment of the composition of the present invention (Example 3), according to the "Guidelines for Determination and Comparison of Dissolution Curves of Ordinary Oral Solid Preparations" issued by the State Food and Drug Administration, a paddle dissolution tester was used, with pH 1.2 as the dissolution medium, to establish an in vitro simulated digestion experiment to evaluate the gastrointestinal tolerance of the test protein. A single whole protein was used as the control group, and two reference proteins (non-gastric coagulation protein whey protein and gastric coagulation protein calcium caseinate) were mainly benchmarked. The "wet weight of clots retained by the sieve" and the "protein content of the dissolution medium" after filtration by the sieve were used to characterize the risk of gastric coagulation protein and the simulated gastric emptying rate, respectively. It was set that "no obvious or less clots were retained by the sieve, and the higher the protein content of the dissolution medium", the gastric coagulation risk of the combined protein was lower and the gastric emptying rate was higher. The combined proteins composed of the three proteins in different proportions, namely, calcium caseinate, concentrated whey protein, and soy protein isolate, were compared in weight ratios of 48:28:24 (combination 2), 23:53:24 (control example 1), and 24:27:49 (control example 2), respectively. The simulated gastric coagulation state and simulated gastric emptying rate presented were compared, thereby screening out the optimal compatibility ratio of mixed proteins with good gastrointestinal tolerance. Comparative studies have confirmed that, compared with two reference proteins, the inventors unexpectedly found that both the compatibility ratios of composition 2 (Scheme 2) and control example 1 (Scheme 1) showed good gastrointestinal tolerance, similar to non-gastric coagulation protein whey protein, better than control example 2 (Scheme 3), and significantly better than gastric coagulation protein calcium caseinate, achieving unexpectedly good gastrointestinal tolerance. The results suggest that the advantage of retaining a large proportion of casein in the formula, replacing part of the whey protein with a specific proportion of soy protein (intermediate protein) (Scheme 2), can show gastrointestinal tolerance similar to that of a formula with a large proportion of whey protein (Scheme 1); on the contrary, a formula with a large proportion of soy protein (intermediate protein) (Scheme 3) shows a slightly increased simulated gastric coagulation phenomenon compared with the formula of Scheme 2, and the simulated gastric emptying rate tends to slow down. The results are not completely consistent with theoretical reasoning, which may be related to the difference in hydrophilicity of the three-dimensional spatial structure of proteins from different sources. In fact, the composition of the present invention is composed of a specific proportion, and this proportion makes it possible to maximize the advantages of the three different protein sources, thereby satisfying the first attribute of the use of the present invention, ensuring the compliance of the composition of the present invention for enteral nutrition support in elderly patients after gastrointestinal tumor resection, and reducing the risk of insufficient protein intake caused by different degrees of gastrointestinal function impairment and digestion and absorption disorders caused by aging, tumors, and gastrointestinal resection trauma.
[0031] In one embodiment of the composition of the present invention (Example 4), a zebrafish 28-day restricted food intake-induced energy-protein malnutrition model was established to simulate the "tube feeding" of clinical patients, and calcium caseinate was used as a reference protein to investigate the weight change, total muscle protein, muscle cholesterol content, muscle water content, muscle ATP and other indicators of the zebrafish at the end of the test. "Small weight loss and large total muscle protein" were set as the main principle for judging good nutritional adequacy, and the combined proteins composed of three protein raw materials in different proportions, i.e., calcium caseinate, concentrated whey protein, and soy protein isolate, were compared in weight ratios of 48:28:24 (composition 2 of the present invention), 23:53:24 (control example 1), and 24:27:49 (control example 2), respectively, on the effects of sustained synthesis of muscle protein and the ability to slow down weight loss, thereby screening out the optimal compatibility ratio of the combined protein. Comparative studies have confirmed that composition 2 of the present invention (scheme 2 idea) has the smallest change in terminal body weight, the highest muscle crude protein content, the highest muscle cholesterol content, and less mobilization of the body to produce ATP energy supply, but there is no difference in muscle water content between groups, indicating that the composition of scheme 2 with a larger proportion of slow protein has a stronger ability to continuously promote zebrafish muscle protein synthesis, thereby significantly inhibiting the progressive weight loss caused by malnutrition, and has higher nutritional adequacy, so it mobilizes less body fat for energy supply and mobilizes less ATP energy supply from the body, and its performance is significantly better than the reference protein calcium caseinate and control examples 1 to 2, followed by the scheme 3 composition with a larger proportion of intermediate protein, while the scheme 1 composition with a larger proportion of fast protein has a weaker ability to continuously promote muscle protein synthesis and maintain the total amount of muscle protein, so the extent of slowing down weight loss is smaller. The above experimental conclusions are consistent with theoretical reasoning, that is, the formula retains the advantage of a larger proportion of casein, and replaces part of the whey protein with a specific proportion of soy protein. Its ability to continuously promote muscle protein synthesis maintains and exceeds the advantages of casein single protein, and is significantly better than the formula with a larger proportion of whey protein or a formula with a larger proportion of soy protein. Therefore, the nutritional composition composed of the composition of the present invention is formulated in a specific proportion. This proportion makes it possible to maximize the advantages of the three different protein sources, thereby satisfying the second attribute achieved by the use of the present invention, ensuring that the composition of the present invention is used for elderly patients after gastrointestinal tumor resection to continuously supplement the required protein, and reduce the risks of progressive weight loss, skeletal muscle atrophy, weakness, fatigue, etc. caused by aging, tumors, restricted food intake, and digestion and absorption disorders.
[0032] In one embodiment of the composition of the present invention (Example 5), a model of increased protein demand after zebrafish tail amputation was established, and the test protein was supplemented on the basis of fish feed feeding to simulate clinical "tube feeding". The tail amputation model group fed with fish feed was used as the control, and the change in the tail fin regeneration area 3 days after postoperative gavage was used as the investigation index. The "larger tail fin area" was set to determine that the higher the nutritional adequacy of the combined protein, the more it could accelerate the body's protein synthesis, repair damaged tissues and promote regeneration. The nutritional adequacy of fast protein isolate whey protein, hydrolyzed whey protein, and combined proteins composed of different proportions, that is, calcium caseinate, concentrated whey protein, and soy protein isolate were compared by weight. The weight ratios were 48:28:24 (composition 2 of the present invention), 23:53:24 (control example 1), and 24:27:49 (control example 2), respectively, and the optimal compatibility ratio with stronger acceleration of wound healing was screened out. Comparative studies confirm that the present invention unexpectedly found that composition 2 can significantly increase the regeneration area of zebrafish tail fin after oral gavage for 3 days after tail amputation, which is significantly better than the model group fed with fish feed, isolated whey protein and control example 1, meeting the increased protein nutritional needs after surgery and showing good nutritional adequacy; on the contrary, control example 2 and hydrolyzed isolated whey protein did not show obvious tissue regeneration under the experimental conditions. Tip: The formula retains the advantage of a large proportion of casein, replaces part of the whey protein with a specific proportion of soy protein (without hydrolyzed whey protein), and increases protein intake on the basis of basic nutrition. It has a strong ability to quickly and continuously promote the synthesis of damaged tissue protein. Therefore, the nutritional composition composed of the composition of the present invention is composed of a specific proportion, which makes it possible to maximize the advantages of the three different protein sources, thereby satisfying the third attribute achieved by the use of the present invention, ensuring that the composition of the present invention is used for elderly patients after digestive tract tumor resection to continuously supplement the required amount of protein, and reducing the risk of delayed wound healing caused by factors such as aging, surgical trauma, postoperative hyperglycemia stress state, and postoperative hypoproteinemia.
[0033] According to the research data of Examples 3 to 5, the inventor unexpectedly discovered that the composition, according to the specific weight ratio of calcium caseinate, concentrated whey protein, and soy protein isolate of 48:28:24, meets the three property requirements of good gastrointestinal tolerance, rapid promotion of wound tissue repair, and continuous enhancement of muscle tissue growth, and is proven to show better effects than the reference protein (gastric coagulation protein calcium caseinate, non-gastric coagulation protein), comparative example 1, and the combined protein of comparative example 2. The next work is to further clarify the protein availability, therapeutic use, clinical use effect, mechanism of action, etc. of the composition of the present invention. The specific description is as follows:
[0034] Example 6 is the in vivo digestibility and protein efficacy ratio (PER) determination of the composition of the present invention. The results show that the apparent digestibility of the composition of the present invention is (91.24±0.56)%, and the true digestibility is (96.09±0.56)%; the apparent digestibility of the reference protein calcium caseinate is (91.96±0.62)%, and the true digestibility is (97.03±0.62)%; there is no significant difference in the in vivo digestibility between the composition of the present invention and calcium caseinate. The PER of the composition of the present invention is 3.85, and the PER of calcium caseinate is 3.76, and there is no statistical difference in the protein efficacy ratios of the two groups; the corrected PER of the composition of the present invention after correction is 2.56. It is particularly noteworthy that the inventor unexpectedly observed that in the third week of the PER test, the composition of the present invention significantly promoted the weight gain of rats, suggesting that the composition continuously enhances the ability to synthesize muscle protein better than the calcium caseinate group, and can maintain the concentration of amino acids in plasma at a higher level for a long time, thereby continuously promoting weight gain, showing the advantage of a special ratio. It can be seen that the composition of the present invention is a digestible high-quality protein, which can be well digested, absorbed and utilized by the body.
[0035] Example 7 is the therapeutic use of the composition of the present invention for elderly patients who are at risk of malnutrition after gastrointestinal tumor resection and the evaluation of clinical use effects. After resection, elderly patients suffer from changes in the anatomical structure of the digestive tract, impaired gastrointestinal function, and reduced digestion and absorption area due to digestive tract tumor diseases and surgery, which leads to limited food intake or decreased digestion and absorption function in patients, and they are very likely to have symptoms of malnutrition (NRS 2002 ≥ 3 points). On the one hand, the body's protein synthesis capacity is insufficient; on the other hand, decomposition and consumption increase, and the body is in a high catabolic state. Therefore, postoperative hypoproteinemia (serum albumin level is less than 35g / L) is common in clinical practice, resulting in slow wound healing and increased weight loss, which directly affects the patient's clinical outcome. The results of clinical observations showed that compared with before the intervention, after 5 days of oral intervention after surgery, the composition of the present invention had good gastrointestinal tolerance, no gastrointestinal intolerance such as nausea, vomiting, abdominal pain, diarrhea, constipation, etc., and good safety of consumption, which ensured the patient's compliance with continuous nutritional support; secondly, the composition of the present invention could significantly improve the nutritional status of the subjects with postoperative hypoproteinemia, significantly increase the levels of serum total protein and albumin, and tissue regeneration could be observed in the wound site of the patients on the 3rd day of intervention, and abnormal phenomena such as redness, swelling, and exudate were significantly alleviated, and the endpoint of the experiment (the 5th day of intervention) significantly promoted the improvement of the patients' wound healing; thirdly, compared with before the intervention, the weight of the composition of the present invention increased slightly (4%) after the intervention, although it was not statistically significant, but it could slow down the progressive weight loss caused by malnutrition due to tumors, surgical trauma, etc., and continuously maintain myosin growth. Finally, it was shown that the protein provided by the specific compatibility ratio of the composition of the present invention can simultaneously meet the three property requirements of good gastrointestinal tolerance, accelerated wound tissue repair, and continuous enhancement of muscle tissue growth, and can meet the nutritional treatment needs of elderly patients after gastrointestinal tumor resection for wound healing and inhibition of weight loss.
[0036] Delayed or weakened wound healing is a problem that plagues elderly patients after gastrointestinal tumor resection. The inventors believe that the supplementation of digestible high-quality protein helps fibroblasts proliferate and accumulate at the wound site, producing collagen to help the wound close. That is to say, at this stage of wound healing, new connective tissue is synthesized, and more than 80% of this tissue is composed of collagen; if there is no sufficient nitrogen source to provide amino acids, collagen cannot be effectively formed. The above clinical research results prove that the composition of the present invention can quickly promote wound healing in elderly patients after gastrointestinal tumor resection. We also understand from Example 5 that the composition can quickly and effectively promote tissue regeneration 3 days after tail amputation, but its influence on the rapid synthesis of wound tissue protein is not yet clear. In view of this, the formation of new blood vessels at the wound site is used to characterize the ability of wound tissue protein synthesis, and the mechanism of action of the composition of the present invention to accelerate wound healing is studied. As described in Example 8, after 2 days of intervention, the composition of the present invention promoted the rapid healing of zebrafish wound tissue by generating 71% of new blood vessels at the wound site, indicating that the composition of the present invention has a strong ability to promote tissue protein synthesis and accelerate the repair and regeneration of wound tissue. This further proves that the special ratio of the formula advantage of the composition of the present invention determines the special amino acid composition and content, so that the amino acid requirements for protein synthesis of wound connective tissue can be better met.
[0037] In summary, the composition of the present invention provides a digestible high-quality protein. Due to its special formula ratio, it can give full play to the advantages of three different protein sources, making it possible to have clinical advantages such as good gastrointestinal tolerance, promotion of wound healing, and continuous enhancement of muscle protein synthesis. Therefore, it can be used for nutritional treatment to promote wound healing and inhibit weight loss in elderly patients after gastrointestinal tumor resection, and comprehensively improve the nutritional status of patients. This may be one of the key points for protein supplementation to give full play to the advantages of disease relief in elderly patients after gastrointestinal tumor resection, which is undoubtedly exciting news. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Attached Figure 1 The composition of the present invention inhibits the pigment recruitment phenotype of the wound site
[0039] Attached Figure 2 Phenotypic diagram of the effect of the composition of the present invention on angiogenesis DETAILED DESCRIPTION
[0040] Example 1 Compounding ratio and protein content of the composition
[0041] 1) Sources of raw materials and protein composition of each component
[0042] The protein sources contained in the compositions of the present invention and comparative examples 1 to 2 are all composed of casein, whey protein and soy protein. As shown in Table 1, the casein used can be selected from any suitable casein source, including micellar casein, caseinate and any mixture thereof, wherein the caseinate refers to casein that has lost its micellar structure, and can be potassium caseinate, calcium caseinate, magnesium caseinate or sodium caseinate, with a protein content (based on a wet basis) of not less than 83.5%, which can be commercially available from Friesland Campina; the whey protein used can be selected from any suitable whey protein source, including concentrated whey protein, isolated whey protein and any mixture thereof, with a protein content (based on a wet basis) of not less than 75.0%, which can be commercially available from Arla Foods Ingredients SA; the soy protein used can be selected from any suitable soy protein source, including soy protein isolate, with a protein content (based on a wet basis) of not less than 85.0%, which can be commercially available from DuPont.
[0043] Table 1 Protein raw material sources and protein contents of the compositions of the present invention and the comparative examples
[0044]
[0045] 2) Compounding ratio of the composition
[0046] The compounding ratios of the three proteins of the composition of the present invention and control examples 1 to 2 are shown in Table 2. Taking the protein sources, composition, and weight ratios of the compositions 1 to 6 listed in Table 1 as an example, compounding according to the weight ratios shown in Table 2, the protein contents of the compositions 1 to 6 of the present invention are shown in Table 2; taking the protein sources, composition, and weight ratios of the components of the composition 2 listed in Table 1 as an example, compounding according to the weight ratios shown in Table 2, the protein contents of the compositions of control examples 1 to 2 are shown in Table 2.
[0047] Table 2 Compounding ratio and protein content of the compositions of the present invention and comparative examples 1 to 2
[0048]
[0049]
[0050] 3) Amino acid score of the composition
[0051] The amino acid scores of proteins were calculated based on the WHO / FAO 2013 scoring model. As shown in Table 3, the amino acid scores of the three compositions were all above 100, with a complete range of essential amino acids and appropriate proportions, and all were high-quality proteins.
[0052] Table 3 Amino acid scores of the compositions of the present invention and the reference examples
[0053]
[0054] Example 2 Preparation method of oral preparation of composition
[0055] Powder: The environmental humidity is controlled below 60%, the temperature is <30°C, and the three raw materials of casein, whey protein and soy protein that meet the quality requirements of protein content are accepted and tested. The dosage of the formula is calculated according to the composition of the present invention (Table 2) shown in Example 1, the materials are prepared, weighed, passed through a 20-mesh sieve, and added to a two-dimensional motion mixer in sequence, and an appropriate amount of silicon dioxide is added. The mixing time is 10 to 30 minutes, the speed is 10 to 20 rpm, and the mixed powder is quantitatively packaged (specification: 10g / bag). The protein content of the finished product (on a wet basis) is not less than 8.3g / bag, the moisture is <5%, and the microbial limit meets the regulations.
[0056] Granules: The ambient humidity is controlled below 60%, the temperature is <30°C, and the three raw materials of casein, whey protein and soy protein that meet the quality requirements of protein content are accepted and tested. The formula dosage is calculated according to the composite weight ratio (Table 2) of the composition of the present invention shown in Example 1, the materials are prepared, weighed, passed through a 20-mesh sieve, added to a fluidized bed granulator in sequence, mixed, sprayed with an appropriate amount of water as a binder for wet granulation, dried at 50-60°C, passed through a 14-mesh sieve, granulated, and quantitatively packaged (specification: 10g / bag). The protein content of the finished product (on a wet basis) is not less than 8.3g / bag, the moisture is <5%, and the microbial limit meets the regulations.
[0057] Oral suspension emulsion: The ambient humidity is controlled below 60%, the temperature is <30°C, and the three raw materials of casein, whey protein and soy protein that meet the quality requirements of protein content are accepted and tested. The formula dosage is calculated according to the composite weight ratio (Table 2) of the composition of the present invention shown in Example 1, the materials are prepared, weighed, passed through a 20-mesh sieve, and added to the liquid preparation tank containing an appropriate amount of purified water in sequence, stirred and mixed, and an appropriate amount of composite emulsifying thickener (mono- and diglycerol fatty acid esters, gellan gum) is added. After shearing, homogenization, constant volume, filling (20mL / bottle) and other processes, sterilized at 121°C for 15min. The finished product protein is not less than 8.3g / bottle, and commercially sterile.
[0058] Example 3 Gastrointestinal Tolerance Evaluation of Composition
[0059] According to the "Guidelines for Determination and Comparison of Dissolution Curves of Ordinary Oral Solid Preparations" issued by the State Food and Drug Administration, a paddle dissolution tester was used to take 9.0 mL of hydrochloric acid, dilute it to 1000 mL with water, shake it well, prepare a dissolution medium with a pH of 1.2, and establish an in vitro simulated digestion experiment (50 rpm, 30 min) to evaluate the gastrointestinal tolerance of the test protein. Based on the fact that the gastrointestinal function of elderly patients after gastrointestinal tumor resection is impaired, which directly affects the secretion and release of gastrointestinal digestive enzymes, and gastrointestinal motility is generally slowed down, the effect of gastrointestinal digestive enzymes on digestion is not considered in the in vitro simulated digestion test, and the in vitro dissolution is set at a lower speed (50 rpm) to simulate the state of impaired gastrointestinal digestive function of patients under specific medical conditions. In the test, if the test protein is not easy to coagulate when in contact with the simulated gastric fluid medium, the probability of protein clot accumulation is small, the gastric tolerance is good, and it can be emptied by the stomach well, showing that the protein content of the dissolution medium filtered by the sieve is high, and the simulated gastric emptying speed is fast, which proves that the risk of delayed gastric emptying or increased gastric residual volume is reduced, which may effectively avoid the risk of intolerance of the upper gastrointestinal tract. This is especially important for patients with digestive and absorption disorders.
[0060] A single whole protein was used as the control group, and two reference proteins (whey protein and calcium caseinate) were used as the benchmark. The "wet weight of the clot retained by the sieve" and the "protein content of the dissolution medium" after filtration by the sieve were used to characterize the risk of gastric coagulation protein and the simulated gastric emptying rate, respectively. It was set that "no obvious or less clots were retained by the sieve, and the higher the protein content of the dissolution medium", the lower the gastric coagulation risk and the higher the gastric emptying rate of the combined protein. The combined proteins composed of the three proteins in different proportions, namely, calcium caseinate, concentrated whey protein, and soy protein isolate, were compared in weight ratios of 48:28:24 (composition 2 of the present invention, scheme 2), 23:53:24 (control example 1, scheme 1), and 24:27:49 (control example 2, scheme 3), respectively. The simulated gastric coagulation state and gastric emptying rate presented at equal protein amounts were (the results are shown in Table 4), thereby screening out the optimal compatibility ratio of mixed proteins with good gastrointestinal tolerance.
[0061] Table 4 Comparison of protein coagulation state in simulated gastric digestion in vitro and protein content in dissolution medium (n=3)
[0062]
[0063] As shown in Table 3, under the conditions of the in vitro simulated gastric digestion test, whey protein showed no obvious gastric coagulation phenomenon, and the amount of protein passing through the 60-mesh screen dissolution medium was 95.7%; calcium caseinate and soy protein isolate produced larger clots, and the amount of protein passing through the 60-mesh screen dissolution medium was 49.4% and 65.2%, respectively, indicating that the simulated gastric emptying rate was significantly slowed down, which is consistent with the research consensus that "whey protein is a non-gastric coagulation protein, casein is a gastric coagulation protein, and soy protein is an intermediate protein". The three mixed proteins have good solubility and dispersibility in the dissolution medium, and all produce less gastric coagulation phenomenon, indicating that the mixed protein improves gastrointestinal tolerance to varying degrees, which is significantly better than single proteins such as calcium caseinate or soy protein isolate. It is worth noting that the inventor unexpectedly found that the simulated gastric coagulation state of composition 2 is similar to that of control example 1, and almost less gastric coagulation phenomenon is produced, and the amount of protein passing through the 60-mesh screen dissolution medium is 91.6% and 90.8%, respectively, and the simulated gastric emptying rate is fast, which is very close to whey protein. The results suggest that retaining the advantage of a larger proportion of casein in the formula and replacing part of the whey protein with a specific proportion of soy protein (intermediate protein) (Scheme 2 idea) shows unexpectedly good gastrointestinal tolerance, which is similar to the formula with a larger proportion of whey protein (Scheme 1 idea); it can be said that the composition of the present invention is a composition composed of a specific proportion, and this proportion makes it possible to maximize the advantages of the three different protein sources, thereby satisfying the first attribute of the use of the present invention, ensuring the compliance of the composition of the present invention for oral or tube feeding nutritional support for elderly patients after gastrointestinal tumor resection, and reducing the risk of insufficient protein intake caused by gastrointestinal function impairment and digestion and absorption disorders due to aging, tumors, and gastrointestinal resection trauma. However, inconsistent with theoretical reasoning, Control Example 2 (Scheme 3) with a higher proportion of intermediate protein showed a slightly increased simulated gastric coagulation phenomenon compared to Composition 2 (Scheme 2) with a higher proportion of slow protein, and the amount of protein in the dissolution medium passing through the 60-mesh sieve was also lower (75.9% vs 91.6%), and the simulated gastric emptying rate was slowed down, indicating that Control Example 2 has an increased risk of gastric coagulation and delayed gastric emptying compared to Composition 2.
[0064] In view of this, according to the evaluation results of the gastric coagulation state of the test protein in the in vitro simulated gastric digestion test and in accordance with the principle of "good tolerability", the compounding ratio of the composition 2 of the present invention (casein: whey protein: soy protein = 48:28:24) and the control example 1 (casein: whey protein: soy protein = 23:53:24) can be preferred.
[0065] Example 4 Evaluation of the ability of the composition to continuously enhance muscle protein synthesis and inhibit weight loss
[0066] Wild-type AB strain adult male zebrafish were selected and randomly divided into groups, with 10 fish in each group. Ordinary fish bait intake was cancelled, and the tested protein was used as the only bait source for zebrafish and the intake was restricted to establish a zebrafish protein malnutrition model caused by restricted feeding under 28-day exercise state. The experiment used calcium caseinate as the reference protein, and calcium caseinate, composition 2 of the present invention and control examples 1-2 were given by gavage, with a dose of 2.481 mg protein / tail, fed once a day, placed at 28°C room temperature for continuous feeding for 28 days, and the weight change, muscle crude protein content, muscle water content, muscle total cholesterol content, muscle ATP content and other indicators of each test group were measured at the end of the experiment, and the t-test method was used to statistically analyze the nutritional adequacy differences of the three compositions (the results are shown in Tables 5-6), setting "smaller weight loss and larger muscle protein" as the main principle, thereby screening out the optimal compatibility ratio of mixed proteins with stronger ability of "continuously enhancing muscle protein synthesis and inhibiting weight loss".
[0067] Table 5 Effects of the tested proteins on body weight changes and muscle crude protein content in zebrafish with insufficient protein intake (n=10)
[0068]
[0069] Note: ① vs calcium caseinate group, **p<0.01, ***p<0.001; ② vs. the composition of the present invention 2, #p<0.05, ### p<0.001
[0070] Table 6 Effects of the tested proteins on muscle water, total cholesterol and ATP content in zebrafish with insufficient protein intake (n=10)
[0071]
[0072] Note: ① vs calcium caseinate group, **p<0.01, ***p<0.001; ② vs. the composition of the present invention 2, #p<0.05, ### p<0.001
[0073] As shown in Tables 4 to 5, there was no significant difference between the pre-test body recombinants, and the weight of each group at the end of the 28-day test decreased to varying degrees, indicating that the zebrafish were in a state of hunger caused by restricted feeding, suggesting that the protein deficiency model caused by insufficient protein intake was successfully established. The end-point weight change of the composition 2 of the present invention (Scheme 2 idea) was the smallest, the muscle crude protein content was the highest, the muscle cholesterol content was higher, and the mobilization of the body to produce less ATP energy supply was less, but there was no difference between the groups in muscle water content, indicating that the composition of Scheme 2 with a large proportion of slow protein continued to promote zebrafish muscle protein synthesis. Strong ability, thereby significantly inhibiting the progressive weight loss caused by malnutrition, with higher nutritional adequacy, so less body fat was mobilized for energy supply, and less ATP was mobilized for energy supply, and the performance was obviously better than the reference protein calcium caseinate and control examples 1 to 2, followed by the composition of Scheme 3 with a large proportion of intermediate protein, and the composition of Scheme 1 with a large proportion of fast protein continued to promote muscle protein synthesis, maintain the total amount of muscle protein. Weak ability, so the amplitude of slowing down weight loss is small, the above experimental conclusions are consistent with theoretical reasoning.
[0074] Researchers generally believe that short-term hunger requires the use of liver glycogen, increasing gluconeogenesis, myosin decomposition and mobilizing fat; long-term hunger further mobilizes fat, reduces myosin decomposition and increases gluconeogenesis. It can be seen that hunger is always related to sugar, fat and protein metabolism, and the tricarboxylic acid cycle is the final metabolic pathway of the three major nutrients, and the tricarboxylic acid cycle produces a large amount of ATP. Therefore, the hungrier the body is, the more energy supply it needs and the more ATP it produces; conversely, the better the sufficiency of nutrient intake, the stronger the ability to resist hunger, the less the body mobilizes its own energy supply, and the less ATP it produces. In view of this, according to the evaluation results of the composition on myosin synthesis and the ability to inhibit weight loss, in accordance with the principle of "optimal nutritional sufficiency", based on the research results that the composition 2 of the present invention "can significantly increase myosin synthesis, reduce muscle fat decomposition, have a high protein nutritional sufficiency, thereby reducing the energy supply of ATP required to resist hunger, and comprehensively improve the nutritional status under hunger", the composition 2 of the present invention (casein: whey protein: soy protein = 48:28:24) can be preferably used as the best compatibility ratio. This ratio makes it possible to maximize the advantages of the three different protein sources, thereby satisfying the second attribute of the use of the present invention and ensuring that the composition of the present invention is used to continuously supplement the required protein for elderly patients after gastrointestinal tumor resection, thereby reducing the risks of progressive weight loss, skeletal muscle atrophy, weakness, fatigue, etc. caused by aging, tumors, restricted food intake, and digestion and absorption disorders.
[0075] Example 5 Evaluation of the Ability of Compositions to Promote Wound Healing
[0076] Wild-type AB strain female adult zebrafish were selected and randomly divided into groups, with 10 fish in each group. Part of the tail fin of the zebrafish was removed to establish a model of increased protein demand for damaged tissue after tail amputation of zebrafish. The tail amputation group fed with ordinary fish feed was used as a model control. The remaining groups were gavaged with composition 2 of the present invention, control examples 1-2, isolated whey protein, and hydrolyzed whey protein on the basis of ordinary fish feed. The doses were set to 111, 333, and 1000 μg / tail, and the fish were fed once a day and cultured at 28°C. After continuous feeding for 3 days after tail amputation, each test group collected photos under a dissecting microscope, and statistical analysis was performed using variance analysis and Dunnett's T-test. The statistical significance of the tail fin regeneration area (A) was used to comprehensively evaluate the promotion effect of the test protein on wound healing (the calculation formula is as follows, and the results are shown in Table 7), and the "larger tail fin area" was set to screen out the optimal compatibility ratio of the mixed protein with a stronger ability to "rapidly repair damaged tissue and promote regeneration".
[0077] Promoting effect on caudal fin regeneration area (%) = [A 供试组 -A 模型组 】 / A 模型组 ×100%
[0078] Table 7 The promoting effect of the tested proteins on the regeneration of damaged caudal fin tissue of zebrafish after tail amputation (n=10)
[0079]
[0080] Note: Compared with the model control group: * p<0.05
[0081] As shown in Table 7, compared with the normal group, the model control group had obvious tail fin damage during modeling. On the third day after tail amputation, the tail fin of the model group had not yet recovered to the size of the normal group, indicating that the protein demand for damaged tissue after zebrafish tail amputation was successfully established. The inventor unexpectedly found that at a dose of 1000 μg protein / tail, composition 2 (Scheme 2 idea) had a significant promoting effect on zebrafish wound healing, which was significantly better than control example 1 (Scheme 1 idea) and isolated whey protein, while control example 2 (Scheme 3 idea) and hydrolyzed whey protein only had a trend of promoting zebrafish tissue regeneration, but the effect was not significant. Tip: On the one hand, similar to the fast protein formula (isolated whey protein and control 1 composition), the second composition of the second scheme with a large proportion of slow protein can also quickly promote the regeneration of tail fin tissue 3 days after tail amputation; on the other hand, the second composition of the second scheme based on the large proportion of slow protein also has a strong ability to continuously promote muscle protein synthesis, thereby showing a better tissue regeneration ability than the fast protein formula (isolated whey protein and control 1 composition), which significantly promotes wound healing. Unexpectedly, the composition of scheme 3 in which the intermediate protein accounted for a larger proportion and the hydrolyzed whey protein did not show significant tissue regeneration ability 3 days after tail amputation, which also provides a basis for selecting complete whey protein rather than hydrolyzed whey protein in the composition of the present invention.
[0082] In view of this, according to the evaluation results of the composition on the regeneration ability of damaged tissues, in accordance with the principle of "optimal nutritional adequacy", based on the research results that the composition 2 of the present invention "can significantly promote wound healing, the composition 2 of the present invention (casein: whey protein: soy protein = 48:28:24) can be preferably used as the optimal compatibility ratio. This ratio makes it possible to maximize the advantages of the three different protein sources, thereby satisfying the third attribute achieved by the use of the present invention, ensuring that the composition of the present invention is used for elderly patients after gastrointestinal tumor resection to continuously supplement the required amount of protein, and reducing the risk of delayed wound healing caused by aging, surgical trauma, postoperative hyperglycemia stress state, postoperative hypoproteinemia, etc.
[0083] Examples 3 to 5 demonstrate that the composition of the present invention in a specific ratio (casein: whey protein: soy protein = 48: 28: 24) has three properties: good gastrointestinal tolerance, rapid promotion of wound healing, and sustained inhibition of weight loss, which is better than control examples 1 to 2 and can meet the nutritional needs of elderly patients after gastrointestinal tumor resection. The following examples 6 to 8 will further verify the protein availability, therapeutic use, clinical use effect, and partial mechanism of action of the composition of the present invention in promoting wound healing.
[0084] Example 6 Protein Availability of the Compositions of the Invention
[0085] Calcium caseinate was used as a reference protein to determine the availability of the composition 2 of the present invention. The "in vivo digestibility" was used to characterize the degree of protein digestion by the body, and the "protein efficacy ratio" was used to measure the body utilization of the protein.
[0086] As shown in Table 8, with reference to AOAC (American Association of Analytical Chemistry) official method 991.29 "Digestibility of Protein in Foods and Food Ingredients" rat bioassay method (first edition in 1991), the apparent digestibility of the composition 2 of the present invention was calculated according to the following formula: 91.24±0.56%, and the true digestibility was 96.09±0.56%; the apparent digestibility of calcium caseinate was 91.96±0.62%, and the true digestibility was 97.03±0.62%; there was no significant difference in the in vivo digestibility of the composition 2 of the present invention and that of calcium caseinate, indicating that the in vivo digestibility of the composition of the present invention is high and has good availability.
[0087] Apparent digestibility = (food nitrogen - fecal nitrogen) / food nitrogen × 100%
[0088] True digestibility = [food nitrogen - (fecal nitrogen - fecal metabolic nitrogen)] / food nitrogen × 100%
[0089] Table 8 In vivo digestibility test results of the composition of the present invention and reference protein (n=10)
[0090]
[0091] As shown in Table 9, referring to the research method of GB Ministry of Agriculture Announcement No. 2031-15-2013 "Safety Testing of Genetically Modified Organisms and Their Products - Protein Efficacy Ratio Experimental Method", the protein efficacy ratio (PER) of the composition 2 of the present invention was calculated to be 3.85 according to the following formula, and the PER of calcium caseinate was 3.76. After statistical analysis, there was no statistical difference in the PER between the two groups; the corrected PER of the composition 2 of the present invention was 2.56. There was no significant difference in the protein efficacy ratio between the composition 2 of the present invention and calcium caseinate, indicating that the composition of the present invention can be digested, absorbed and utilized by the body and has good availability.
[0092] Protein efficacy ratio (PER) = weight gain of rats during the test period / total protein intake during the test period
[0093] Corrected protein efficacy ratio = (protein efficacy ratio of the composition of the present invention / protein efficacy ratio of calcium caseinate) × 2.5
[0094] Table 9_Comparison of the composition of the present invention with reference proteins Protein efficacy ratio and corrected protein efficacy ratio (n=10)
[0095] Group Weight gain (g) Total food intake (g) Protein intake (g) PER Corrected PER Calcium Caseinate 133.4±18.6 362.3±43.5 35.80±4.30 3.76±0.19 - Composition 2 of the present invention 148.6±20.9 371.5±38.4 38.31±3.96 3.85±0.21 2.56
[0096] Considering that the nutritional intervention period for the determination of protein efficacy ratio is 28 days (4 weeks), in order to further compare the dynamic difference in the degree of utilization of the composition of the present invention and the reference protein by the body, we calculated and statistically analyzed the weight gain, protein intake and protein efficacy ratio at 4 time points (weeks 1 to 4) during the entire test period. As shown in Table 10, the inventor unexpectedly found that compared with the initial body weight, the total weight gain and protein efficacy ratio of the rats in the composition group of the present invention in the third week increased significantly, and there was a significant difference compared with the calcium caseinate group (P < 0.05 and P < 0.01), and the total weight gain and protein efficacy ratio in the fourth week showed an increasing trend compared with the calcium caseinate group, but there was no statistical difference (P> 0.05). It is further confirmed that the special ratio (casein: whey protein: soy protein = 48:28:24) designed by the second idea of the present invention, which retains casein as a larger proportion and replaces part of the whey protein with the intermediate protein soy protein, can make it possible to maximize the advantages of these three different protein sources. Therefore, it can be used for elderly patients after gastrointestinal tumor resection to continuously promote the increase of lean body mass and reduce the risks of progressive weight loss, skeletal muscle atrophy, weakness, fatigue, etc. caused by aging, tumors, restricted food intake, and digestion and absorption disorders. It is significantly better than the reference protein calcium caseinate.
[0097] Table 10 Dynamic detection results of the utilization degree of the composition of the present invention and the reference protein by the body (n=10)
[0098]
[0099]
[0100] Note: Compared with calcium caseinate group, *P<0.05; **P<0.01
[0101] In summary, the protein provided by the composition of the present invention has good availability, can be digested, absorbed and utilized by the body, can sustainably promote the growth of body weight, and has good nutritional adequacy.
[0102] Example 7 Therapeutic use of the composition of the present invention and its clinical effect
[0103] In order to verify the therapeutic use of the composition of the present invention and its clinical effect, 55 elderly inpatients with nutritional risks (NRS 2002 total score ≥ 3 points), hypoproteinemia (25< serum albumin ALB < 35 g / L) and need to increase protein intake after gastrointestinal tumor resection were selected by self-before-after control method. The patients were 62±10 years old, weighed 66.6±11.0 kg, 27 males (49%) and 28 females (51%). The disease distribution was gastric cancer, colon cancer, rectal cancer, gallbladder cancer and other gastrointestinal tumor resection surgeries (patient baseline data are shown in Table 11); with the period before intervention (conventional nutritional support) as the control, all patients received continuous enteral nutrition with the composition of the present invention 2 on the basis of clinical diagnosis and treatment and conventional nutritional support. The intervention lasted for 5 days, 30 g / day (26.07 g protein / day) and 10 g / time (8.69 g protein / time), to investigate the effects of the composition of the present invention on the food safety (gastrointestinal tolerance) and nutritional adequacy (changes in serum protein levels, wound healing, and weight changes) of the patient population after the test endpoint. Among them, the wound healing system is a grade indicator: Grade A healing refers to obvious tissue regeneration at the wound site, without redness, swelling, or exudate; Grade B healing refers to tissue regeneration at the wound site, with non-purulent exudate; Grade C healing refers to purulent infection in the wound, which heals after open drainage.
[0104] Table 11 Baseline data of elderly patients undergoing digestive tract tumor resection enrolled in the clinical study of the composition of the present invention
[0105]
[0106] Table 12 Incidence of gastrointestinal tolerance symptoms during the intervention period of the composition of the present invention (n=55)
[0107]
[0108] Table 13 Changes in serum total protein and albumin levels before and after intervention with the composition of the present invention (n=55)
[0109] project Before intervention After intervention Difference (back - front) p-value Rate of change (%) Serum total protein (g / L) 54.74±4.20 59.44±7.07 <![CDATA[4.69±7.11 *** ]]> 0.000 8.95±13.44 Serum albumin (g / L) 31.24±2.58 33.31±4.61 <![CDATA[2.07±5.10 ** ]]> 0.002 7.36±17.71
[0110] Note: Compared with before intervention, *** p<0.001; ** p<0.01
[0111] Table 14 Healing rates of different levels of wound healing during the intervention period of the composition of the present invention (n=55)
[0112] project Intervention day 3 Intervention Day 5 Grade A healing rate (cases / incidence) 28 / 50.9% 55 / 100.0% Grade B healing rate (cases / incidence) 27 / 49.1% 0 / 0.0% Grade C healing rate (cases / incidence) 0 / 0% 0 / 0.0% Efficiency 100.0% 100.0%
[0113] Table 15 Body weight changes before and after intervention with the composition of the present invention (n=55)
[0114] project Before intervention (kg) After intervention (kg) p-value Rate of change (%) weight 66.6±11.0 69.3±10.1 p>0.05 4.1
[0115] As shown in Tables 12 to 15, during the intervention period of the composition 2 of the present invention, no gastrointestinal symptoms such as nausea, vomiting, abdominal pain, abdominal distension and diarrhea were found in 55 patients, indicating that the gastrointestinal tolerance of the composition was good. Compared with before the intervention, the composition 2 of the present invention can significantly improve the serum total protein level (P < 0.001, increased by 8.95% ± 13.44%) and serum albumin level (P < 0.01, increased by 7.36% ± 17.71%) of hospitalized patients after surgery, indicating that the composition of the present invention can significantly improve the nutritional status of patients with protein deficiency under specific medical conditions. Wound healing was observed in 55 patients on the third day after intervention, of which 28 patients (50.9%) had obvious tissue regeneration at the wound site, without redness, swelling or exudate; 27 patients (49.1%) had tissue regeneration at the wound site, with non-purulent exudate, and the effective rate was 100%; all patients had significantly improved wound healing on the fifth day of intervention, with obvious tissue regeneration at the wound site, without abnormalities such as redness, swelling or exudate, indicating that the composition of the present invention can quickly promote tissue wound repair and shorten wound healing time. After intervention, the weight of the patient increased by 4.1% compared with that before intervention, but there was no statistical significance, indicating that the composition of the present invention can significantly inhibit weight loss under special medical conditions and maintain weight continuously. The above data indicate that the composition of the present invention has good gastrointestinal tolerance in elderly patients after gastrointestinal tumor resection, can significantly improve protein malnutrition caused by hypoproteinemia, quickly promote wound healing and inhibit weight loss, and the protein consumption safety and nutritional adequacy are good.
[0116] Example 8 Mechanism of action of the composition of the present invention in promoting wound healing
[0117] 2dpf transgenic vascular fluorescent zebrafish were selected, and glacial acetic acid was injected into the trunk of the zebrafish (at the intersection of the notochord and the cloaca) to establish a zebrafish wound healing model. Zebrafish with the same degree of wound damage were selected, and the composition 2 of the present invention (concentrations of 67, 200 and 600 μg / mL) was fed in a water bath to set up a model control group and a normal control group (zebrafish were treated with fish water). Each group (well) was treated with 30 zebrafish, and the capacity of each group (well) was 3mL. While the test sample was treated, 0.2‰ of methylene blue was given to each group (well) to inhibit the growth of fungi. The six-well plate was placed in a 28°C incubator for culture. After 2 days of treatment, 14 zebrafish were randomly selected from each group to collect pictures under a fluorescence microscope, and the statistical significance of the sum of the opacity of the wound site and the incidence of new blood vessels was used to evaluate the promotion of wound healing by the composition of the present invention.
[0118] Table 16 The promoting effect of the composition of the present invention on wound healing in zebrafish (n=14)
[0119]
[0120] Note: Compared with the model control group: *** p<0.001
[0121] As shown in Table 16, compared with the normal control group, the opacity of the wound site of zebrafish in the model control group increased significantly, indicating that the zebrafish in the model group had obvious vascular damage; 2 days later, 50% of new blood vessels appeared in the model control group, indicating that the zebrafish tissue damage model was successfully established. Compared with the model group, the total opacity (pixels) of the wound site of zebrafish in the composition 2 (200 μg / mL) group of the present invention decreased significantly, and the inhibitory effect on pigment recruitment in the wound site was 11% (see Appendix Figure 1 ), the incidence of new blood vessels in the wound site was 71% (see Appendix Figure 2 ), indicating that the composition 2 of the present invention can promote the wound healing of zebrafish by rapidly promoting the formation of new blood vessels at the wound site.
[0122] The above embodiments are intended to illustrate the essential contents of the present invention, but are not intended to limit the protection scope of the present invention.
[0123] It should be understood by those skilled in the art that the technical solution of the present invention may be modified or replaced by equivalents without departing from the essence and protection scope of the technical solution of the present invention.
Claims
1. A nutritional composition composed of casein, whey protein and soy protein for preparing a product for rapidly promoting wound healing and continuously inhibiting weight loss in elderly patients after gastrointestinal tumor resection, characterized in that: The composition comprises: 48 parts by weight of casein, 28 parts by weight of whey protein and 24 parts by weight of soy protein, and the protein content is not less than 83.0% on a wet basis; the casein is selected from micellar casein or caseinate or any mixture thereof, the caseinate is selected from potassium caseinate, sodium caseinate, calcium caseinate and magnesium caseinate, and the protein content is not less than 83.5% on a wet basis; the whey protein is selected from concentrated whey protein, isolated whey protein and any mixture thereof, and the protein content is not less than 75.0% on a wet basis; the soy protein is selected from isolated soy protein, and the protein content is not less than 85.0% on a wet basis.
2. The use according to claim 1, characterized in that The composition has good gastrointestinal tolerance, and can accelerate wound healing and slow down weight loss in elderly patients after gastrointestinal tumor resection by rapidly promoting wound tissue regeneration and continuously enhancing muscle protein synthesis.
3. The use according to any one of claims 1 to 2, wherein the product is a special medical formula food, health food or enteral nutrition functional food for rapidly promoting wound healing and continuously inhibiting weight loss in elderly patients after gastrointestinal tumor resection, characterized in that: The composition according to claim 1 is mixed with auxiliary materials to prepare an oral preparation, and the oral preparation is any one of powder, granule and suspension emulsion.
Citation Information
Patent Citations
High protein liquid enteral nutritional composition
CN102083329B
Highly digestible protein-rich nutritional compositions, uses thereof, and methods for preparing the same
CN111836555A
Nutritional composition for wound healing
CN1893839B
Enteral nutrient for oncotherapy and preparation method thereof
CN106668835A
